Business
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of
About this update from Surrozen, Inc.
[{"type":"text","content":"-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and compelling preclinical data highlighting the potential for lacrimal gland and lung programs SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company. “2022 promises to be a transformational year for Surrozen, as it marks our planned entry into the clinic for two novel therapeutic candidates,” said Craig Parker, President and Chief Executive Officer of Surrozen. “Our priorities are focused on demonstrating the clinical potential for our lead programs in liver and intestine, advancing our novel Wnt therapeutics discovery pipeline and continuing our progression toward a fully integrated biotech company. Furthermore, we have expanded to a third therapeutic area in ophthalmology with the recent nomination of lead candidate SZN-413.” Parker continued, “Our discovery programs continue to identify new areas where our Wnt platform technologies could have therapeutic impact, including lacrimal gland and lung. We will continue to integrate our biological insights and proprietary discoveries in pursuit of our vision to develop Wnt therapeutics aimed at halting or reversing progression in a broad spectrum of serious diseases.” Recent Highlights Lead Product CandidatesSZN-1326 for Moderate to Severe Ulcerative Colitis and SZN-043 for Severe Alcoholic HepatitisSZN-1326 is the first development candidate designed using Surrozen’s SWAPTM technology and targets the Wnt signaling pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, SZN-1326 has been shown to activate Wnt signaling in the intestine, stimulate intestinal epithelial regeneration, reduce inflammation and reduce disease activity. Surrozen is developing SZN-1326 for moderate to severe inflammatory bowel disease. SZN-043 is the first development candidate designed using Surrozen’s SWEETSTM technology. In preclinical animal ...